NexImmune Reports New Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings

February 16, 2023

(24/7 MARKET NEWS) – NexImmune, Inc. (Nasdaq:NEXI) stated, this morning, that new positive, preclinical data will be presented in an abstract titled “Prior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy” at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida, highlighting how Tumor Associated Antigen (TAA)-specific AIM ACT CD8 T cells are superior to polyclonal peripheral blood CD4 T cells, naive CD8 T cells, and bulk CD8 T cells as effectors of BiTE-mediated killing in vivo.

NexImmune is at $0.51, up $0.10 (+24.37%), on 400 thousand premarket shares.

Its 52-week trading range is $ 0.1947 to $4.91. It’s cleared over three months’ worth of resistance levels and, if it can break through the $0.78 resistance, on strong trading volume, it looks like it wants to challenge the $1.25 level.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.